NCT07044687 - Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Venetoclax

Oral Tablet

DRUG

Azacitidine

Subcutaneous (SC) Injection

DRUG

Azacitidine

Intravenous (IV) Injection

Trial Locations (5)

RECRUITING

Rajiv Gandhi Cancer Institute And Research Centre /ID# 268293, New Delhi

RECRUITING

LMMF's Deenanath Mangeshkar Hospital & Research Center /ID# 268781, Pune

RECRUITING

Sahyadri Super Speciality Hospital /ID# 272074, Pune

RECRUITING

Basavatarakam Indo American Cancer Hospital & Research Institute /ID# 268692, Hyderabad

RECRUITING

Cancer Institute (Wia) /ID# 268695, Chennai